Shares of Tocagen Inc (NASDAQ:TOCA) have received an average broker rating score of 2.00 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company.
Brokerages have set a one year consensus price target of $23.67 for the company, according to Zacks. Zacks has also assigned Tocagen an industry rank of 114 out of 265 based on the ratings given to its competitors.
TOCA has been the subject of a number of analyst reports. Stifel Nicolaus reissued a “buy” rating and set a $24.00 price objective on shares of Tocagen in a report on Tuesday, July 25th. Zacks Investment Research raised Tocagen from a “sell” rating to a “hold” rating in a report on Thursday, September 21st.
Several institutional investors have recently added to or reduced their stakes in the stock. Granahan Investment Management Inc. MA bought a new position in shares of Tocagen in the third quarter valued at about $392,000. BBR Partners LLC bought a new position in shares of Tocagen in the third quarter valued at about $181,000. JPMorgan Chase & Co. raised its holdings in shares of Tocagen by 52.9% in the third quarter. JPMorgan Chase & Co. now owns 630,375 shares of the company’s stock valued at $7,886,000 after buying an additional 218,100 shares during the last quarter. California State Teachers Retirement System bought a new position in shares of Tocagen in the second quarter valued at about $179,000. Finally, EcoR1 Capital LLC bought a new position in shares of Tocagen in the second quarter valued at about $18,074,000. 37.88% of the stock is owned by institutional investors and hedge funds.
Tocagen (TOCA) opened at $10.38 on Wednesday. Tocagen has a twelve month low of $8.60 and a twelve month high of $17.95. The company has a current ratio of 6.03, a quick ratio of 6.03 and a debt-to-equity ratio of 0.07.
Tocagen (NASDAQ:TOCA) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.02). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. sell-side analysts anticipate that Tocagen will post -2.88 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.thestockobserver.com/2017/11/15/zacks-brokerages-set-23-67-price-target-for-tocagen-inc-toca.html.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.